Form 8-K - Current report:
SEC Accession No. 0001193125-23-167893
Filing Date
2023-06-15
Accepted
2023-06-15 16:07:02
Documents
12
Period of Report
2023-06-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d491519d8k.htm   iXBRL 8-K 28897
  Complete submission text file 0001193125-23-167893.txt   154489

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA oric-20230614.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20230614_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20230614_pre.xml EX-101.PRE 11714
6 EXTRACTED XBRL INSTANCE DOCUMENT d491519d8k_htm.xml XML 3480
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

EIN.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 231017383
SIC: 2834 Pharmaceutical Preparations